TSLP and autoimmune disease: These ex vivo studies demonstrated that the TAVO101 inhibited TSLP-driven allergic inflammation responses from its target cells which laid the foundation for its potential as a therapeutic treatment of TSLP-mediated allergic, chronic inflammatory and autoimmune diseases.